Aarti Pharmalabs Q1 PAT up 49%, to add Rs 149 Cr intermediate capacity
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 20.3 pts more than Nifty Microcap 250 and 20.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aarti Pharmalabs reported Q1FY27 standalone revenue of Rs 534.59 Cr, up 42% YoY, with PAT at Rs 71.31 Cr, up 49%. Consolidated revenue rose 39% to Rs 535.80 Cr and PAT jumped 65% to Rs 76.14 Cr. Board approved Rs 149 Cr capex for a new 405 KL intermediate block to be added within 1 year, funded by internal accruals and borrowings, to serve intermediate and CDMO customers. Rashesh Gogri to become MD and Hetal Gogri Gala to move to Executive Director from Oct 1, 2026. Q1FY25 figures were restated for a forex derivative fair value loss.
Strong Q1 growth signals demand momentum. Rs 149 Cr capex signals expansion, partly debt funded. Key leadership change at the top.